Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 3/20 | 0.75 |
| ▸ | BCHE | P06276 | 2/20 | 0.75 |
| ▸ | MAOA | P21397 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | CDC25B | P30305 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | TDP2 | O95551 | 2/20 | 0.46 |
| ▸ | S100A4 | P26447 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthraquinone SCHEMBL22026730 | 0.88 | MAOA (0.95) | CES1BCHEMAOAMEN1KMT2A | |
| Anthrone SCHEMBL8617645 | 0.86 | MAOA (0.90) | CES1BCHEMAOAMEN1KMT2A | |
| SCHEMBL29684343 | 0.86 | CES1 (0.67) | CES1BCHEMAOAMEN1KMT2A | |
| SCHEMBL976344 | 0.86 | CES1 (0.67) | CES1BCHEMAOAMEN1KMT2A | |
| SCHEMBL29355339 | 0.86 | CES1 (1.00) | CES1BCHEMAOAMEN1KMT2A | |
| SCHEMBL669542 | 0.86 | CES1 (1.00) | CES1BCHEMAOAMEN1KMT2A | |
| SCHEMBL32671773 | 0.86 | CES1 (0.67) | CES1BCHEMAOAMEN1KMT2A | |
| SCHEMBL29848510 | 0.86 | CES1 (0.67) | CES1BCHEMAOAMEN1KMT2A | |
| SCHEMBL569873 | 0.85 | — | — | |
| SCHEMBL31070117 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454258-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | Merck Patent GmbH (DE) | 2012-05-23 | — | — | EP | claimed |
| WO-2011006569-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2011-01-20 | — | — | WO | claimed |
| EP-4227452-A1 | FILAMENT, MATERIAL, AND MATERIAL MANUFACTURING METHOD | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-20200283454-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-09-10 | — | — | US | disclosed |
| EP-3686201-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| EP-2454258-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | Merck Patent GmbH (DE) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011006569-A1 | HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2011-01-20 | — | — | WO | disclosed |
| US-4256742-A | Antidepressant oxime ethers of dibenzocycloheptaziridones | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1981-03-17 | — | — | US | disclosed |
| EP-0009611-A1 | 1a, 1Ob-Dihydrodibenzo(3,4,6,7)cyclohept(1,2-b)azirin-6(1H)-one oximes, process for their preparation and pharmaceutical compositions containing the antidepressant compounds among these oximes | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283454-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | RTF2, POLRMT, RTF1 | CES1 1677/4885BCHE 1533/4885MAOA 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.